Active	Status	Sponsor type	Region	Phase	Filter
12 Active 4 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Thureau, Sebastien
ZOSTER, NCT03951493: Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases	Recruiting	3	225	Europe	Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions, Hypo-fractured radiotherapy in stereotactic conditions	Institut Cancerologie de l'Ouest	Vertebral Metastasis	11/23	11/23
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24
STEREO-OS, NCT03143322: Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases	Active, not recruiting	N/A	168	Europe	SBRT	UNICANCER, National Cancer Institute, France	Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Prostate Cancer, Bone Metastases	07/25	07/27
EVRARD, Camille Mrs
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Recruiting	3	864	Europe, Canada, Japan, US, RoW	Dostarlimab, Placebo	GlaxoSmithKline	Neoplasms, Head and Neck	05/28	07/29
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24
EREMISS, NCT03793361: Phase II Study of Regorafenib as Maintenance Therapy	Completed	2	127	Europe	Regorafenib, stivarga, Placebo	Centre Oscar Lambret	Metastatic Soft Tissue Sarcoma	03/24	09/24
LAP-NET1, NCT05546853: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma	Active, not recruiting	1	52	Europe	NP137, Oxaliplatin, Irinotecan, Calcium levofolinate, 5 FU	University Hospital, Grenoble, NETRIS Pharma	Pancreatic Ductal Adenocarcinoma	03/26	03/27
EXOSARC, NCT03800121: Study of Exosomes in Monitoring Patients With Sarcoma	Recruiting	N/A	34	Europe	Blood samples, Localized sarcoma, Metastatic sarcoma	Centre Georges Francois Leclerc	Sarcoma	11/24	11/25
CLIMES, NCT05787197: ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases	Recruiting	N/A	232	Europe		GERCOR - Multidisciplinary Oncology Cooperative Group	Metastatic Colorectal Cancer, Circulating Tumor DNA	09/25	06/27
COPERNIC, NCT05487248: A Study of On-treatment CtDNA Changes in Chemo-refractory Colorectal Cancer Patients	Recruiting	N/A	103	Europe	Blood Sample Collection	Jules Bordet Institute, Hoffmann-La Roche	Unresectable Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer, Candidate for Third-line or Subsequent Lines of Therapy	04/26	12/26
NCT04530890: Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer	Recruiting	N/A	1000	Europe	Blood samples	Poitiers University Hospital	Breast Cancer, Digestive Cancer, Gynecologic Cancer, Circulating Tumor DNA, Exosomes	09/30	09/30
Ridder, Mischa De
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24